Pfizer (PFE) closed the latest trading day at $29.42, indicating a -0.83% change from the previous session's end. This move lagged the S&P 500's daily loss of 0.19%. Meanwhile, the Dow gained 0.09%, ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...